Search of anti-adriamycin antibodies in serum of cancer patients under chemotherapic treatment

A. Verdina, R. Tonachella, E. Colella, G. Falasca, Rosella Galati

Research output: Contribution to journalArticle

Abstract

The exposure to DNA reactive carcinogens is known to elicit a specific humoral immunological response, with the production of antibodies towards the carcinogen adducts. In analogy to chemical carcinogens, any chemotherapic, like Adriamycin, undergoes the same adduct formation, and for this reason could elicit specific antibodies. In this case we can suppose that an eventual immunological response could influence the efficacy of chemotherapy. The aim of this study was to verify if adriamycin adducted to DNA or transport proteins can elicit an immunological response of specific anti-adriamycin (ADM) antibodies in sera of 43 cancer patients treated with the drug. No specific antibodies were detected in these individuals. The lack of anti-adriamycin antibodies suggests that the therapeutic exposure to the drug does not elicit a specific immunological response.

Original languageEnglish
Pages (from-to)337-340
Number of pages4
JournalJournal of Experimental and Clinical Cancer Research
Volume21
Issue number3
Publication statusPublished - Sep 2002

Fingerprint

Doxorubicin
Anti-Idiotypic Antibodies
Carcinogens
Serum
Neoplasms
Antibodies
DNA
Therapeutics
Pharmaceutical Preparations
Antibody Formation
Carrier Proteins
Drug Therapy

Keywords

  • Adriamycin
  • Immunological response
  • Specific antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Search of anti-adriamycin antibodies in serum of cancer patients under chemotherapic treatment. / Verdina, A.; Tonachella, R.; Colella, E.; Falasca, G.; Galati, Rosella.

In: Journal of Experimental and Clinical Cancer Research, Vol. 21, No. 3, 09.2002, p. 337-340.

Research output: Contribution to journalArticle

@article{f30834d8ba464a298b54f777cb183e6f,
title = "Search of anti-adriamycin antibodies in serum of cancer patients under chemotherapic treatment",
abstract = "The exposure to DNA reactive carcinogens is known to elicit a specific humoral immunological response, with the production of antibodies towards the carcinogen adducts. In analogy to chemical carcinogens, any chemotherapic, like Adriamycin, undergoes the same adduct formation, and for this reason could elicit specific antibodies. In this case we can suppose that an eventual immunological response could influence the efficacy of chemotherapy. The aim of this study was to verify if adriamycin adducted to DNA or transport proteins can elicit an immunological response of specific anti-adriamycin (ADM) antibodies in sera of 43 cancer patients treated with the drug. No specific antibodies were detected in these individuals. The lack of anti-adriamycin antibodies suggests that the therapeutic exposure to the drug does not elicit a specific immunological response.",
keywords = "Adriamycin, Immunological response, Specific antibodies",
author = "A. Verdina and R. Tonachella and E. Colella and G. Falasca and Rosella Galati",
year = "2002",
month = "9",
language = "English",
volume = "21",
pages = "337--340",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "3",

}

TY - JOUR

T1 - Search of anti-adriamycin antibodies in serum of cancer patients under chemotherapic treatment

AU - Verdina, A.

AU - Tonachella, R.

AU - Colella, E.

AU - Falasca, G.

AU - Galati, Rosella

PY - 2002/9

Y1 - 2002/9

N2 - The exposure to DNA reactive carcinogens is known to elicit a specific humoral immunological response, with the production of antibodies towards the carcinogen adducts. In analogy to chemical carcinogens, any chemotherapic, like Adriamycin, undergoes the same adduct formation, and for this reason could elicit specific antibodies. In this case we can suppose that an eventual immunological response could influence the efficacy of chemotherapy. The aim of this study was to verify if adriamycin adducted to DNA or transport proteins can elicit an immunological response of specific anti-adriamycin (ADM) antibodies in sera of 43 cancer patients treated with the drug. No specific antibodies were detected in these individuals. The lack of anti-adriamycin antibodies suggests that the therapeutic exposure to the drug does not elicit a specific immunological response.

AB - The exposure to DNA reactive carcinogens is known to elicit a specific humoral immunological response, with the production of antibodies towards the carcinogen adducts. In analogy to chemical carcinogens, any chemotherapic, like Adriamycin, undergoes the same adduct formation, and for this reason could elicit specific antibodies. In this case we can suppose that an eventual immunological response could influence the efficacy of chemotherapy. The aim of this study was to verify if adriamycin adducted to DNA or transport proteins can elicit an immunological response of specific anti-adriamycin (ADM) antibodies in sera of 43 cancer patients treated with the drug. No specific antibodies were detected in these individuals. The lack of anti-adriamycin antibodies suggests that the therapeutic exposure to the drug does not elicit a specific immunological response.

KW - Adriamycin

KW - Immunological response

KW - Specific antibodies

UR - http://www.scopus.com/inward/record.url?scp=0036737096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036737096&partnerID=8YFLogxK

M3 - Article

C2 - 12385574

AN - SCOPUS:0036737096

VL - 21

SP - 337

EP - 340

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 3

ER -